Statera Biopharma, Inc. filed its 10-K on Oct 06, 2022 for the period ending Dec 31, 2021. In this report its auditor, B F Borgers CPA PC, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0007 USD | 0.00% | 0.00% | +16.67% |
2023 | Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs. | CI |
2023 | Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index | CI |
1st Jan change | Capi. | |
---|---|---|
+16.67% | 50.81K | |
+26.37% | 48.16B | |
-1.01% | 41.73B | |
+41.87% | 41.03B | |
-5.31% | 28.77B | |
+9.34% | 25.59B | |
-21.69% | 18.96B | |
+6.23% | 12.92B | |
+26.99% | 12.03B | |
-3.38% | 11.77B |
- Stock Market
- Equities
- STAB Stock
- News Statera Biopharma, Inc.
- Statera Biopharma, Inc. Auditor Raises 'Going Concern' Doubt